186 related articles for article (PubMed ID: 23981262)
1. Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre M; Sapède C; Moore N; ; Bilbault P; Blin P; Chopy D; Evans D; Gueyffier F; Lacoin L; Malbezin M; Micallef J; Morlet-Vigier D; Muller S; Oger E; Plétan Y; Pons G; Verpillat P; Vigneau C
Therapie; 2013; 68(4):241-52. PubMed ID: 23981262
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoepidemiolgy: regulatory basis, methodological approaches and scope].
Ahid S; Belaguide K; Cherrah Y
East Mediterr Health J; 2012 Jan; 18(1):85-93. PubMed ID: 22360016
[TBL] [Abstract][Full Text] [Related]
3. Methods in pharmacoepidemiology.
Sommet A; Pariente A
Therapie; 2019 Apr; 74(2):187-197. PubMed ID: 30819408
[TBL] [Abstract][Full Text] [Related]
4. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.
Weldeselassie YG; Whitaker HJ; Farrington CP
Epidemiol Infect; 2011 Dec; 139(12):1805-17. PubMed ID: 21849099
[TBL] [Abstract][Full Text] [Related]
5. A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics.
Luo X; Cappelleri JC; Frush K
Curr Med Res Opin; 2007 May; 23(5):1015-24. PubMed ID: 17526119
[TBL] [Abstract][Full Text] [Related]
6. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
[TBL] [Abstract][Full Text] [Related]
7. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia.
; Andersen M; Bergman U; Choi NK; Gerhard T; Huang C; Jalbert J; Kimura M; Kimura T; Kubota K; Lai EC; Ooba N; Park BJ; Pratt N; Roughead EE; Sato T; Setoguchi S; Shin JY; Sundström A; Yang YH
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):700-4. PubMed ID: 23653370
[No Abstract] [Full Text] [Related]
8. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making.
Etminan M; Gill S; Fitzgerald M; Samii A
J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278
[TBL] [Abstract][Full Text] [Related]
9. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacoepidemiology: definitions, problems, methodology].
Bégaud B; Dangoumau J
Therapie; 2000; 55(1):113-7. PubMed ID: 10860010
[TBL] [Abstract][Full Text] [Related]
11. Guidelines for good database selection and use in pharmacoepidemiology research.
Hall GC; Sauer B; Bourke A; Brown JS; Reynolds MW; LoCasale R
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):1-10. PubMed ID: 22069180
[TBL] [Abstract][Full Text] [Related]
12. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
Tian F; Liao X; Xie YM
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
[TBL] [Abstract][Full Text] [Related]
13. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
Abou Taam M; Ferard C; Rocle P; Maison P
Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
[TBL] [Abstract][Full Text] [Related]
14. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
15. Symmetry analysis for monitoring safety of newly marketed drugs.
Kubota K
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoepidemiology and Drug Safety's special issue on validation studies.
Chun DS; Lund JL; Stürmer T
Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):123-125. PubMed ID: 30714240
[No Abstract] [Full Text] [Related]
17. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
18. Case-population studies in pharmacoepidemiology.
Capellà D; Pedrós C; Vidal X; Laporte JR
Drug Saf; 2002; 25(1):7-19. PubMed ID: 11820909
[TBL] [Abstract][Full Text] [Related]
19. Exposure-time-varying hazard function ratios in case-control studies of drug effects.
Guess HA
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):81-92. PubMed ID: 16287211
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoepidemiology in pregnancy.
Benevent J; Araujo M; Hurault-Delarue C; Montastruc JL; Sommet A; Lacroix I; Damase-Michel C
Therapie; 2019 Apr; 74(2):289-300. PubMed ID: 30797568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
